Abstract:Aberrant expression of programmed death ligand 1 (PD-L1) on tumor cells impedes antitumor immunity and instigates immune evasion. The remarkable efficacy of immune checkpoint blockade has been confirmed in various solid tumors. However, the correlation between PD-L1 expression and host immunological landscape remains of considerable controversy in non-small cell lung cancer (NSCLC). In the present study, PD-L1 expression and CD8+ tumor-infiltrating lymphocyte (TIL) infiltration levels were determined by immunohistochemistry (IHC) in tumor sections of 138 NSCLC patients. The expression level of PD-L1 was positively correlated with the abundance of CD8 + TILs (p < 0.0001). Furthermore, no constitutive expression of PD-L1 was observed in the majority of six NSCLC cell lines detected by Western blot; but exposure to interferon-γ (IFN-γ), a primary cytokine secreted by activated CD8+ T cells, prominently increased PD-L1 expression. Notably, a significantly positive association was determined within PD-L1, CD8 and IFN-γ gene expression by qRT-PCR, which was corroborated by RNA-sequencing from TCGA lung cancer dataset. These findings demonstrate that PD-L1 expression indicates an adaptive immune resistance mechanism adopted by tumor cells in the aversion of immunogenic destruction by CD8+ TILs. Both higher expression of PD-L1 and infiltration of CD8+ TILs were correlated with superior prognosis (p = 0.044 for PD-L1; p = 0.002 for CD8). Moreover, Cox multivariate regression analysis showed that the combination of PD-L1 and CD8 were independent prognostic factors, which was more accurate in prediction of prognosis in NSCLC than individually. Finally, we found that IFN-γ induced the upregulation of PD-L1 in NSCLC cells, mainly through the JAK/STAT1 signaling pathway. In conclusion, PD-L1 expression is mainly induced by activated CD8+ TILs via IFN-γ in the immune milieu and indicates pre-existing adaptive immune response in NSCLC.

A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity

Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion

An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function

Distinct Roles of Programmed Death Ligand 1 Alternative Splicing Isoforms in Colorectal Cancer

Identification and characterization of an alternative cancer-derived PD-L1 splice variant

PD-1 and its ligands are important immune checkpoints in cancer

Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion